ArticleOncogene2026
Functional deficiency of circadian regulator PER2 enhances breast cancer susceptibility and progression with immunosuppression.
Article in Oncogene, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Circadian rhythm (CR) governs systemic and tissue physiological homeostasis by regulating sleep-wake cycles, hormone secretion, and metabolism. CR disruption (CRD), such as shift work, has been associated with increased cancer risk, particularly female breast cancer (BC), yet the mechanisms underlying breast tumorigenesis and immunosuppression resulting from a specific clock gene dysfunction remain unclear. Here, we identify that circadian regulator Period 2 (PER2) is significantly downregulated in BC and correlates with poor prognosis. PER2 functional deficiency mice (PAS-B domain deletion, Per2
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.